Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for AMRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
June 30, 2026 443.62M
March 31, 2026 449.41M
December 31, 2025 459.28M
September 30, 2025 458.89M
June 30, 2025 464.92M
March 31, 2025 473.69M
December 31, 2024 486.18M
September 30, 2024 531.38M
June 30, 2024 551.88M
March 31, 2024 545.94M
December 31, 2023 552.10M
September 30, 2023 553.15M
June 30, 2023 569.13M
March 31, 2023 584.79M
December 31, 2022 595.33M
September 30, 2022 587.83M
June 30, 2022 580.04M
March 31, 2022 641.11M
December 31, 2021 667.10M
September 30, 2021 642.50M
June 30, 2021 645.32M
March 31, 2021 634.61M
December 31, 2020 627.50M
September 30, 2020 607.26M
June 30, 2020 602.76M
Date Value
March 31, 2020 585.78M
December 31, 2019 608.26M
September 30, 2019 595.90M
June 30, 2019 149.09M
March 31, 2019 140.87M
December 31, 2018 152.33M
September 30, 2018 -52.83M
June 30, 2018 -46.69M
March 31, 2018 -16.66M
December 31, 2017 -65.10M
September 30, 2017 -46.11M
June 30, 2017 -38.74M
March 31, 2017 -28.80M
December 31, 2016 -9.154M
September 30, 2016 15.19M
June 30, 2016 -164.42M
March 31, 2016 -156.14M
December 31, 2015 -129.19M
September 30, 2015 -111.09M
June 30, 2015 -91.35M
March 31, 2015 -61.82M
December 31, 2014 -88.45M
September 30, 2014 -67.56M
June 30, 2014 -49.98M
March 31, 2014 -57.59M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Neurocrine Biosciences, Inc. 3.694B
Cellectis SA 41.07M
Alkermes Plc 1.809B
Akari Therapeutics Plc 18.60M
Liquidia Corp. 195.11M

Shareholders Equity (Quarterly) Related Metrics